2027 Texas Lung Cancer Conference

The 5th Annual Texas Lung Cancer Conference (TLC 2027) will convene over 120 leading national experts, rising faculty, and community-based specialists for two days of CE-accredited, case-driven education in thoracic oncology. Designed for practicing physicians and multidisciplinary oncology professionals, TLC 2027 will focus on the most pressing advances in lung cancer diagnosis, treatment selection, multidisciplinary care, and patient-centered implementation. 

Program Highlights: 

• Precision Diagnostics and Early Detection: NGS, liquid biopsy, MRD, and lung cancer screening, with concise updates and panel discussion on practical integration into clinical workflows.
• Early-Stage and Locally Advanced NSCLC: Separate focused sessions on targeted therapy and immunotherapy, including adjuvant, neoadjuvant/perioperative, non-surgical stage III management, radiation, and surgical considerations.
• Advanced NSCLC Targeted Therapy Deep Dives: EGFR including exon 20 insertion, ALK, ROS1, RET, NTRK, NRG1, BRAF, MET, KRAS, and HER2, using rapid evidence updates followed by extended academic and community expert discussion.
• Advanced NSCLC Immunotherapy: Current standards with PD(L)1 plus or minus chemotherapy, dual checkpoint inhibition, bispecific antibodies, ADC-immunotherapy combinations, toxicity considerations, and patient-centered decision-making.
• Small Cell Lung Cancer: Limited-stage and extensive-stage disease, first-line standards, T-cell engagers, salvage therapy, and new directions in SCLC care.
• Rare Thoracic Tumors and Clinical Challenges: Mesothelioma, NUT carcinoma, thymic malignancies, transformation to SCLC or squamous histology, brain metastases and leptomeningeal disease, and surgery for stage IV NSCLC.
• Novel Strategies and Tools for Tomorrow’s Oncologist: Next-generation ADCs, radioligands, tumor treating fields and devices, bronchoscopic interventions, artificial intelligence, cellular therapy, statistics, policy, advocacy, and the business of oncology.
• Engaging Formats: Poster session and welcome reception, rapid-fire updates, interactive panels, a keynote presentation, structured debate, and non-CE breakfast and lunch symposia for deeper dives into career development, SCLC, EGFR/HER2, and KRAS.

Every session is designed for practical take-home application—equipping participants with updated evidence, strategic frameworks, and real-world insights to improve patient outcomes. With robust faculty–audience interaction, curated networking opportunities, and a dynamic Austin setting, TLC 2027 offers an unmatched opportunity to engage with leaders shaping thoracic oncology today and tomorrow.